A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer

NCT06483425 · tracked via the Priya Life Science China tracker

Sponsor

Tongji Hospital

Phase

Observational

Started

2024-03-01

Last updated

2024-07-03

Condition(s) studied

Ovarian CancerBiomarker

Investigational drug(s) / intervention(s)

Sequencing of DNA, RNA, and Proteins

Sequencing of DNA, RNA, and Proteins: Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.

Study summary

This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Patients diagnosed with ovarian cancer. * Willingness to undergo biomarker testing. * Ability to provide informed consent for participation in the study. Exclusion Criteria: * Inability to comply with study requirements or follow-up visits. * Previous participation in a conflicting clinical trial.

Primary outcome measure(s)

Biomarker explorarion — 5 years
Blood, tumor, and other samples should be sequenced by RNA-seq, Next-Generation Sequencing, or proteomics to identify specific biomarkers associated with treatment response and prognosis in ovarian cancer.

Trial sites (1)

Facility	City	Region	Status
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei

More Tongji Hospital trials in China

Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing Recruiting

Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis) Recruiting

Mindfulness Intervention on Minimally Invasive Vascular Surgery Starting soon

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis Recruiting

Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer Starting soon

Other trials for the same condition

A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer Recruiting

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors Recruiting

Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer Recruiting

Application of Cardiophrenic Lymphadenectomy in Advanced Ovarian Cancer: A Single-Center Prospective Exploratory Study Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06483425 on ClinicalTrials.gov ↗ ← All trials in China